Hep C deaths fall by 20% after DAAs made available, but more to do: report

The number of people with hepatitis C dying from liver disease has plummeted by 20% thanks to the availability of direct-acting antiviral (DAA) therapies, according to new data presented at the Australasian Viral Hepatitis Conference in Adelaide on 14 August. Professor Greg Dore, head of the Viral Hepatitis Clinical Research Program at the Kirby Institute, ...

Already a member?

Login to keep reading.

© 2021 the limbic